A single TCR alpha-chain with dominant peptide recognition in the allorestricted HER2/neu-specific T cell repertoire
- PMID: 20042572
- DOI: 10.4049/jimmunol.0902155
A single TCR alpha-chain with dominant peptide recognition in the allorestricted HER2/neu-specific T cell repertoire
Abstract
T cells can recognize tumor cells specifically by their TCR and the transfer of TCR-engineered T cells is a promising novel tool in anticancer therapies. We isolated and characterized four allorestricted TCRs with specificity for the HER2/neu-derived peptide 369 (HER2(369)) demonstrating high peptide specificity. PBMCs transduced with especially one TCR, HER2-1, mediated specific tumor reactivity after TCR optimization suggesting that this TCR represents a potential candidate for targeting HER2 by TCR-transduced effector cells. Another TCR showed high-peptide specificity without tumor reactivity. However, the TCR alpha-chain of this TCR specifically recognized HER2(369) not only in combination with the original beta-chain but also with four other beta-chains of the same variable family deriving from TCRs with diverse specificities. Pairing with one beta-chain derived from another HER2(369)-specific TCR potentiated the chimeric TCRs in regard to functional avidity, CD8 independency, and tumor reactivity. Although the frequency of such TCR single chains with dominant peptide recognition is currently unknown, they may represent interesting tools for TCR optimization resulting in enhanced functionality when paired to novel partner chains. However, undirected mispairing with novel partner chains may also result in enhanced cross-reactivity and self-reactivity. These results may have an important impact on the further design of strategies for adoptive transfer using TCR-transduced T cells.
Similar articles
-
Specific roles of each TCR hemichain in generating functional chain-centric TCR.J Immunol. 2015 Apr 1;194(7):3487-500. doi: 10.4049/jimmunol.1401717. Epub 2015 Feb 20. J Immunol. 2015. PMID: 25710913 Free PMC article.
-
A common TCR V-D-J sequence in V beta 13.1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis.J Immunol. 1999 Sep 15;163(6):3530-8. J Immunol. 1999. PMID: 10477628
-
Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.J Immunol. 2003 Feb 15;170(4):2186-94. doi: 10.4049/jimmunol.170.4.2186. J Immunol. 2003. PMID: 12574392
-
Regulator T cells: specific for antigen and/or antigen receptors?Scand J Immunol. 2003 May;57(5):399-409. doi: 10.1046/j.1365-3083.2003.01249.x. Scand J Immunol. 2003. PMID: 12753496 Review.
-
TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.Curr Opin Immunol. 2015 Apr;33:16-22. doi: 10.1016/j.coi.2015.01.003. Epub 2015 Jan 22. Curr Opin Immunol. 2015. PMID: 25618219 Free PMC article. Review.
Cited by
-
Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection.Life Sci Alliance. 2019 Mar 15;2(2):e201900367. doi: 10.26508/lsa.201900367. Print 2019 Apr. Life Sci Alliance. 2019. PMID: 30877233 Free PMC article.
-
Analysis of thymic generation of shared T-cell receptor α repertoire associated with recognition of tumor antigens shows no preference for neoantigens over wild-type antigens.Cancer Med. 2023 Jun;12(12):13486-13496. doi: 10.1002/cam4.6002. Epub 2023 Apr 28. Cancer Med. 2023. PMID: 37114587 Free PMC article.
-
Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer.Front Immunol. 2019 Jun 28;10:1485. doi: 10.3389/fimmu.2019.01485. eCollection 2019. Front Immunol. 2019. PMID: 31316521 Free PMC article.
-
Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.Cancer Res. 2013 Aug 1;73(15):4820-9. doi: 10.1158/0008-5472.CAN-12-3457. Epub 2013 May 30. Cancer Res. 2013. PMID: 23722540 Free PMC article.
-
Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.Cells. 2020 Jul 22;9(8):1757. doi: 10.3390/cells9081757. Cells. 2020. PMID: 32707982 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous